Artesunate ( DrugBank: Artesunate )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 2 |
| 66 | IgA腎症 | 1 |
| 96 | クローン病 | 1 |
18. 脊髄小脳変性症（多系統萎縮症を除く。）
臨床試験数 : 71 / 薬物数 : 99 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04921930 (ClinicalTrials.gov) | July 1, 2021 | 31/5/2021 | Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) | Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Artesunate in Friedreich Ataxia | Friedreich Ataxia | Drug: Artesunate Oral Product | Institut National de la Santé Et de la Recherche Médicale, France | Imagine Institute | Not yet recruiting | 16 Years | 65 Years | Male | 20 | Phase 1/Phase 2 | NULL |
| 2 | EUCTR2021-000171-36-FR (EUCTR) | 23/03/2021 | 22/01/2021 | PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA (FA) | PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA | Friedreich Ataxia MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: artesunate | INSERM | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 22 | Phase 1;Phase 2 | France |
66. IgA腎症
臨床試験数 : 255 / 薬物数 : 255 - (DrugBank : 79) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000038104 | 2020-09-01 | 2020-09-10 | Efficacy and safety of Artesunate for patients with IgA nephropathy: a multicenter, double-blind, randomized, placebo-controlled trial. | Efficacy and safety of Artesunate for patients with IgA nephropathy: a multicenter, double-blind, randomized, placebo-controlled trial. | IgA nephropathy | Group 1:Artesunate 100mg (50mg/Bid);Group 2:Artesunate 50mg (25mg/Bid);The control group:Placebo; | Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine | NULL | Recruiting | Both | Group 1:40;Group 2:40;The control group:40; | China |
96. クローン病
臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04713631 (ClinicalTrials.gov) | January 2021 | 3/12/2020 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine | Crohn's Disease | Drug: Artesunate;Drug: Curcumin;Drug: Placebo A;Drug: Placebo C | Sanjay Gandhi Postgraduate Institute of Medical Sciences | St George's University of London, London, UK | Not yet recruiting | 18 Years | 65 Years | All | 40 | Phase 2 | India |